Lynkuet
- Prescription status not stated
- Urinary and reproductive system, hormones
- Active substance
- Elinzanetant
- Made by
- Bayer AG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Treatment of moderate to severe vasomotor symptoms (VMS).
From the official label · 2026-09-30 · European Medicines Agency
How it works
From the US prescribing label for the same active substance (LYNKUET). It describes the substance, not this exact product.
LYNKUET is a neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist.
Inhibition of Substance P and Neurokinin B through antagonism of NK1 and NK3 receptor signaling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons can modulate neuronal activity in thermoregulation associated with hot flashes.
Elinzanetant is primarily metabolized by CYP3A4 to yield three major active metabolites, M18/21, M27, and M30/34.
Effect of Food No clinically significant differences in elinzanetant pharmacokinetics were observed following administration with a high-calorie, high-fat meal containing approximately 1000 calories (500-600 calories from fat, 250 calories from carbohydrates, and 150 calories from protein).
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-06-16
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Bayer AG |
|---|---|
| Active substance | Elinzanetant |
| Used in | Urinary and reproductive system, hormones |
| Classification | G02CX07 · Urinary and reproductive system, hormones |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2025-11-17 |
| Last updated by the regulator | 2026-09-11 |
| EMA product number | EMEA/H/C/006298 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).